ANGO241115C12500
- 0.10
- 0.000.00%
AngioDynamics Newsroom
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's Is How to Trade
Investors in AngioDynamics (NASDAQ:ANGO) Have Unfortunately Lost 77% Over the Last Three Years
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
AngioDynamics Launches Long-term Study of NanoKnife for Prostate Cancer
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
CCORF Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $12
AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Otsuka Holdings Co (OtherOTSKF) and AngioDynamics (ANGO)
AngioDynamics' NanoKnife System Gains CPT Codes for Prostate and Liver Treatments
AngioDynamics Announces American Medical Association's CPT Editorial Panel Grants Category I CPT for Irreversible Electroporation (IRE) in Prostate and Liver
CEO, President & Director of AngioDynamics James Clemmer Buys 4.4% More Shares
Insider Trading Activity Heats Up: Tuesday's Top Buys and Sells in US Stocks
AngioDynamics (NASDAQ:ANGO Shareholders Incur Further Losses as Stock Declines 20% This Week, Taking Three-year Losses to 76%
Oppenheimer Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $13
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
AngioDynamics Is Maintained at Buy by Canaccord Genuity
AngioDynamics Price Target Cut to $12.00/Share From $13.00 by Canaccord Genuity
AngioDynamics Analyst Ratings
H.C. Wainwright Maintains AngioDynamics(ANGO.US) With Buy Rating, Maintains Target Price $14